# Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine

> **NCT00285402** · PHASE2 · UNKNOWN · sponsor: **Ariston Pharmaceuticals, Inc.** · enrollment: 198 (estimated)

## Conditions studied

- Migraine
- Migraine Headache
- Migraine Disorders
- Migraine With Aura
- Migraine Without Aura

## Interventions

- **DRUG:** AST-726 Low dose
- **DRUG:** AST-726 High dose
- **DRUG:** AST-726 Placebo

## Key facts

- **NCT ID:** NCT00285402
- **Lead sponsor:** Ariston Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-05
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2008-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00285402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00285402, "Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00285402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*